Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk c19hcq.org Ozturk et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,150 patients in Turkey Lower mortality with HCQ (not stat. sig., p=0.14) Ozturk et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa271 Favors HCQ Favors control
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey
Ozturk et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa271
Ozturk et al., Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant.., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa271
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1210 hospitalized patients in Turkey focused on chronic kidney disease, haemodialysis and renal transplant patients, but also showing lower mortality with HCQ. Subject to confounding by indication.
risk of death, 43.9% lower, RR 0.56, p = 0.14, treatment 165 of 1,127 (14.6%), control 6 of 23 (26.1%), NNT 8.7, CQ/HCQ.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ozturk et al., 4 Dec 2020, retrospective, Turkey, peer-reviewed, 70 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Nephrol Dial Transplant (2020) 35: 2083–2095 doi: 10.1093/ndt/gfaa271 Savas Ozturk1, Kenan Turgutalp2, Mustafa Arici 3, Ali Riza Odabas4, Mehmet Riza Altiparmak5, Zeki Aydin6, Egemen Cebeci1, Taner Basturk7, Zeki Soypacaci8, Garip Sahin9, Tuba Elif Ozler10, Ekrem Kara11, Hamad Dheir12, Necmi Eren13, Gultekin Suleymanlar14, Mahmud Islam 15, Melike Betul Ogutmen16, Erkan Sengul17, Yavuz Ayar18, Murside Esra Dolarslan19, Serkan Bakirdogen20, Seda Safak21, Ozkan Gungor22, Idris Sahin23, Ilay Berke Mentese24, Ozgur Merhametsiz25, Ebru Gok Oguz26, Dilek Gibyeli Genek27, Nadir Alpay28, Nimet Aktas29, Murat Duranay30, Selma Alagoz31, Hulya Colak32, Zelal Adibelli33, Irem Pembegul34, Ender Hur35, Alper Azak36, Dilek Guven Taymez37, Erhan Tatar38, Rumeyza Kazancioglu39, Aysegul Oruc40, Enver Yuksel41, Engin Onan42, Kultigin Turkmen43, Nuri Baris Hasbal 44, Ali Gurel45, Berna Yelken46, Tuncay Sahutoglu 47, Mahmut Gok4, Nurhan Seyahi5, Mustafa Sevinc 7, Sultan Ozkurt9, Savas Sipahi48, Sibel Gokcay Bek13, Feyza Bora14, Bulent Demirelli16, Ozgur Akin Oto21, Orcun Altunoren22, Serhan Zubeyde Tuglular24, Mehmet Emin Demir 25, Mehmet Deniz Ayli26, Bulent Huddam27, Mehmet Tanrisev49, Ilter Bozaci38, Meltem Gursu39, Betul Bakar30, Bulent Tokgoz50, Halil Zeki Tonbul42, Alaattin Yildiz21, Siren Sezer51 and Kenan Ates52 1 Department of Nephrology, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey, 2Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Mersin University Training and Research Hospital, Mersin, Turkey, 3Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey, 4Department of Nephrology, University of Health Sciences, Sultan 2.Abdulhamid Han Training and Research Hospital, Istanbul, Turkey, 5Department of Internal Medicine, Division of Nephrology, Istanbul University – Cerrahpasa Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 6Department of Nephrology, Darica Farabi Training and Research Hospital, Kocaeli, Turkey, 7Department of Nephrology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey, 8Department of Internal Medicine, Division of Nephrology, Izmir Katip Celebi University, Atatürk Training and Research Hospital, Izmir, Turkey, 9Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey, 10Department of Internal Medicine, Division of Nephrology, University of Health Sciences, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey, 11Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey, 12Department of Internal Medicine, Division of Nephrology, Sakarya University Training and Research Hospital, Sakarya, Turkey, 13Department of Nephrology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, 14Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Akdeniz University, Antalya, Turkey, 15Department of Nephrology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey, 16Department of Nephrology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, 17Department of Nephrology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey, 18Department of Nephrology, Bursa City Hospital, Bursa, Turkey, 19Department of Nephrology, University of Health..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit